{"protocolSection":{"identificationModule":{"nctId":"NCT01862874","orgStudyIdInfo":{"id":"V501-122"},"secondaryIdInfos":[{"id":"132237","type":"REGISTRY","domain":"JAPIC-CTI"},{"id":"2015-002931-16","type":"EUDRACT_NUMBER"},{"id":"V501-122","type":"OTHER","domain":"Merck Protocol Number"},{"id":"2015","type":"NIH","link":"https://reporter.nih.gov/quickSearch/2015"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)","officialTitle":"A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men"},"statusModule":{"statusVerifiedDate":"2019-03","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-06-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-08-30","type":"ACTUAL"},"completionDateStruct":{"date":"2017-08-30","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-22","studyFirstSubmitQcDate":"2013-05-22","studyFirstPostDateStruct":{"date":"2013-05-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-07-30","resultsFirstSubmitQcDate":"2018-07-30","resultsFirstPostDateStruct":{"date":"2018-08-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-03-25","lastUpdatePostDateStruct":{"date":"2019-04-02","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"A study to evaluate the efficacy and tolerability of V501 (quadrivalent Human Papilloma Virus \\[HPV\\] \\[Type 6, 11, 16 and 18\\] L1 Virus-Like Particle vaccine, GARDASIL™) in healthy, 16- to 26-year old Japanese males. The hypotheses tested are: 1) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection compared with placebo, and 2) V501 reduces the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, condyloma acuminata, penile/perianal/perineal intraepithelial neoplasia, or penile, perianal, or perineal cancer compared with placebo."},"conditionsModule":{"conditions":["Anogenital Human Papilloma Virus Infection","Condyloma Acuminata"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":1124,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V501","type":"EXPERIMENTAL","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.","interventionNames":["Biological: V501"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"V501","description":"Formulated with aluminum hydroxyphosphate sulfate (AAHS) adjuvant","armGroupLabels":["V501"],"otherNames":["GARDASIL™","Quadrivalent HPV (Type 6, 11, 16 and 18) L1 Virus-Like Particle vaccine"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Formulated with AAHS adjuvant","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection","description":"Persistent infection was defined as 1) polymerase chain reaction (PCR) positive to HPV Type 6, 11, 16, or 18 in 2 consecutive anogenital or biopsy samples collected ≥4 months apart, or 2) Pathology Panel consensus diagnosis of condyloma acuminate, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal, or perineal cancer and PCR detection of HPV Type 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The combined incidence of HPV Type 6, 11, 16, or 18 persistent infection detected in samples from ≥2 consecutive visits ≥6 months apart was assessed.","timeFrame":"Up to Month 36"},{"measure":"Percentage of Participants With Maximum Temperature ≥37.5°C Reported on the Vaccination Report Card","description":"Body temperature (oral or oral equivalent) was recorded on the Vaccination Report Card (VRC). The percentage of participants with a maximum temperature ≥37.5°C was summarized.","timeFrame":"Up to 5 days after any vaccination"},{"measure":"Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized.","timeFrame":"Up to 5 days after any vaccination"},{"measure":"Percentage of Participants With a Systemic Adverse Event","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE was summarized.","timeFrame":"Up to 15 days after any vaccination"},{"measure":"Percentage of Participants With a Vaccine-related Systemic Adverse Event","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. Vaccine-related AEs are those that were deemed possibly, probably, or definitely related to vaccine administration by the investigator. The percentage of participants with a vaccine-related systemic AE was summarized.","timeFrame":"Up to 15 days after any vaccination"}],"secondaryOutcomes":[{"measure":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection or Disease","description":"Persistent infection was defined as 1) polymerase chain reaction (PCR) positive to HPV Type 6, 11, 16, or 18 in 2 consecutive anogenital or biopsy samples collected ≥4 months apart, or 2) Pathology Panel consensus diagnosis of condyloma acuminate, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal, or perineal cancer and PCR detection of HPV Type 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The incidence of persistent infection detected in samples from ≥2 consecutive visits ≥6 months apart was assessed. Disease was defined as HPV Type 6, 11, 16, or 18-related condyloma acuminate, PIN, penile, perianal, or perineal cancer. The combined incidence of HPV Type 6, 11, 16, or 18 persistent infection or disease was assessed.","timeFrame":"Up to Month 36"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Japanese\n* No clinical evidence of gross genital lesion suggesting sexually-transmitted disease and no clinically present external genital warts\n* Other inclusion criteria will be discussed with the investigator during screening\n\nExclusion Criteria:\n\n* History of known prior vaccination with an HPV vaccine or plans to receive one outside the study\n* History of external genital warts\n* History of severe allergic reaction that required medical intervention\n* Received immune globulin or blood-derived products in the past 6 months or plan to receive any before Month 7 of the study\n* History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV), lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition\n* Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids and certain regimens of systemic corticosteroids\n* Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections\n* Ongoing alcohol or drug abuse within the past 12 months","healthyVolunteers":true,"sex":"MALE","minimumAge":"16 Years","maximumAge":"26 Years","stdAges":["CHILD","ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}]},"referencesModule":{"references":[{"pmid":"30797638","type":"RESULT","citation":"Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, Sawata M, Tanaka Y. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine. 2019 Mar 14;37(12):1651-1658. doi: 10.1016/j.vaccine.2019.01.069. Epub 2019 Feb 20."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"A total of 1129 participants were screened and 1124 were randomized.","groups":[{"id":"FG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"FG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","comment":"Randomized participants","numSubjects":"562"},{"groupId":"FG001","comment":"Randomized participants","numSubjects":"562"}]},{"type":"Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"561"},{"groupId":"FG001","numSubjects":"562"}]},{"type":"Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"539"},{"groupId":"FG001","numSubjects":"542"}]},{"type":"Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"530"},{"groupId":"FG001","numSubjects":"532"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"483"},{"groupId":"FG001","numSubjects":"485"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"79"},{"groupId":"FG001","numSubjects":"77"}]}],"dropWithdraws":[{"type":"Randomized not treated","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"26"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Withdrawn by parent/guardian","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"BG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"562"},{"groupId":"BG001","value":"562"},{"groupId":"BG002","value":"1124"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22.6","spread":"2.1"},{"groupId":"BG001","value":"22.6","spread":"2.0"},{"groupId":"BG002","value":"22.6","spread":"2.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"562"},{"groupId":"BG001","value":"562"},{"groupId":"BG002","value":"1124"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"562"},{"groupId":"BG001","value":"562"},{"groupId":"BG002","value":"1124"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection","description":"Persistent infection was defined as 1) polymerase chain reaction (PCR) positive to HPV Type 6, 11, 16, or 18 in 2 consecutive anogenital or biopsy samples collected ≥4 months apart, or 2) Pathology Panel consensus diagnosis of condyloma acuminate, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal, or perineal cancer and PCR detection of HPV Type 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The combined incidence of HPV Type 6, 11, 16, or 18 persistent infection detected in samples from ≥2 consecutive visits ≥6 months apart was assessed.","populationDescription":"Participants who were seronegative at Day 1 and PCR negative from Day 1 through Month 7 to the relevant HPV type, received all 3 vaccinations, did not deviate from the study protocol in ways that might interfere with vaccine efficacy, and had ≥1 follow-up visit after Month 7.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Cases per 100 person-years of follow-up","timeFrame":"Up to Month 36","typeUnitsAnalyzed":"Person-years follow-up","denomUnitsSelected":"Person-years follow-up","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"497"},{"groupId":"OG001","value":"498"}]},{"units":"Person-years follow-up","counts":[{"groupId":"OG000","value":"1137"},{"groupId":"OG001","value":"1123"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"1.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"One-sided exact test","paramType":"Vaccine Efficacy","paramValue":"85.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"52.7","ciUpperLimit":"97.3","estimateComment":"Vaccine efficacy is defined as the percentage reduction in relative risk for the V501 group versus the placebo group.","otherAnalysisDescription":"If the lower bound of the 95% confidence interval for vaccine efficacy excludes 0%, then superiority of the V501 group is demonstrated."}]},{"type":"PRIMARY","title":"Percentage of Participants With Maximum Temperature ≥37.5°C Reported on the Vaccination Report Card","description":"Body temperature (oral or oral equivalent) was recorded on the Vaccination Report Card (VRC). The percentage of participants with a maximum temperature ≥37.5°C was summarized.","populationDescription":"Participants who received ≥1 study vaccination and had follow-up data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 5 days after any vaccination","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"557"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7"},{"groupId":"OG001","value":"3.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of maximum temperature ≥37.5°C","pValue":"0.256","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"-1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-3.5","ciUpperLimit":"0.9","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."}]},{"type":"PRIMARY","title":"Percentage of Participants With an Injection-site Adverse Event Prompted on the Vaccination Report Card","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with an injection-site AE prompted on the VRC (erythema, pain, and swelling) was summarized.","populationDescription":"Participants who received ≥1 study vaccination and had follow-up data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 5 days after any vaccination","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"554"},{"groupId":"OG001","value":"559"}]}],"classes":[{"title":"Injection-site erythema","categories":[{"measurements":[{"groupId":"OG000","value":"24.5"},{"groupId":"OG001","value":"21.6"}]}]},{"title":"Injection-site pain","categories":[{"measurements":[{"groupId":"OG000","value":"54.9"},{"groupId":"OG001","value":"48.5"}]}]},{"title":"Injection-site swelling","categories":[{"measurements":[{"groupId":"OG000","value":"21.3"},{"groupId":"OG001","value":"14.5"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Injection-site erythema","nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of injection-site erythema","pValue":"0.251","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"2.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.1","ciUpperLimit":"7.9","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."},{"groupIds":["OG000","OG001"],"groupDescription":"Injection-site pain","nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of injection-site pain","pValue":"0.033","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"6.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.5","ciUpperLimit":"12.2","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."},{"groupIds":["OG000","OG001"],"groupDescription":"Injection-site swelling","nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of injection-site swelling","pValue":"0.003","statisticalMethod":"Miettinen & Nurminen","paramType":"Risk Difference (RD)","paramValue":"6.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.3","ciUpperLimit":"11.3","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."}]},{"type":"PRIMARY","title":"Percentage of Participants With a Systemic Adverse Event","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. The percentage of participants with a systemic AE was summarized.","populationDescription":"Participants who received ≥1 study vaccination and had follow-up data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 15 days after any vaccination","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"554"},{"groupId":"OG001","value":"559"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.4"},{"groupId":"OG001","value":"15.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of systemic AEs","paramType":"Risk Difference (RD)","paramValue":"-0.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-5.2","ciUpperLimit":"3.3","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."}]},{"type":"PRIMARY","title":"Percentage of Participants With a Vaccine-related Systemic Adverse Event","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant which does not necessarily have a causal relationship with study drug. An AE can therefore be any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug or a protocol-specified procedure, whether or not considered related to the study drug or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the study drug or protocol-specified procedure is also an AE. Vaccine-related AEs are those that were deemed possibly, probably, or definitely related to vaccine administration by the investigator. The percentage of participants with a vaccine-related systemic AE was summarized.","populationDescription":"Participants who received ≥1 study vaccination and had follow-up data available.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 15 days after any vaccination","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"554"},{"groupId":"OG001","value":"559"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4"},{"groupId":"OG001","value":"5.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","nonInferiorityComment":"Statistical testing of no difference in incidence of vaccine-related systemic AEs","paramType":"Risk Difference (RD)","paramValue":"-1.6","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.1","ciUpperLimit":"0.8","estimateComment":"Risk difference (V501 - placebo) was estimated using the Miettinen \\& Nurminen method."}]},{"type":"SECONDARY","title":"Combined Incidence of HPV Type 6, 11, 16, or 18-related Persistent Infection or Disease","description":"Persistent infection was defined as 1) polymerase chain reaction (PCR) positive to HPV Type 6, 11, 16, or 18 in 2 consecutive anogenital or biopsy samples collected ≥4 months apart, or 2) Pathology Panel consensus diagnosis of condyloma acuminate, penile/perianal/perineal intraepithelial neoplasia (PIN), penile, perianal, or perineal cancer and PCR detection of HPV Type 6, 11, 16, or 18 in an adjacent section and PCR positive for the same HPV type at a separate adjacent visit. The incidence of persistent infection detected in samples from ≥2 consecutive visits ≥6 months apart was assessed. Disease was defined as HPV Type 6, 11, 16, or 18-related condyloma acuminate, PIN, penile, perianal, or perineal cancer. The combined incidence of HPV Type 6, 11, 16, or 18 persistent infection or disease was assessed.","populationDescription":"Participants who were seronegative at Day 1 and PCR negative from Day 1 through Month 7 to the relevant HPV type, received all 3 vaccinations, did not deviate from the study protocol in ways that might interfere with vaccine efficacy, and had ≥1 follow-up visit after Month 7.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Cases per 100 person-years at risk","timeFrame":"Up to Month 36","typeUnitsAnalyzed":"Person-years follow-up","denomUnitsSelected":"Person-years follow-up","groups":[{"id":"OG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."},{"id":"OG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"498"},{"groupId":"OG001","value":"498"}]},{"units":"Person-years follow-up","counts":[{"groupId":"OG000","value":"1148"},{"groupId":"OG001","value":"1132"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3"},{"groupId":"OG001","value":"1.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","statisticalMethod":"One-sided exact test","paramType":"Vaccine Efficacy","paramValue":"86.5","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"55.2","ciUpperLimit":"97.4","estimateComment":"Vaccine efficacy is defined as the percentage reduction in relative risk for the V501 versus the placebo group.","otherAnalysisDescription":"If the lower bound of the 95% confidence interval for vaccine efficacy excludes 0%, superiority of the V501 group is demonstrated."}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 36 months","description":"The at-risk population was participants who received ≥1 study vaccination and had follow-up data available","eventGroups":[{"id":"EG000","title":"V501","description":"Participants received V501 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.","deathsNumAffected":0,"deathsNumAtRisk":554,"seriousNumAffected":0,"seriousNumAtRisk":554,"otherNumAffected":329,"otherNumAtRisk":554},{"id":"EG001","title":"Placebo","description":"Participants received placebo 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Follow-up was up to Month 36.","deathsNumAffected":1,"deathsNumAtRisk":559,"seriousNumAffected":1,"seriousNumAtRisk":559,"otherNumAffected":303,"otherNumAtRisk":559}],"seriousEvents":[{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":554},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":559}]}],"otherEvents":[{"term":"Injection-site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":217,"numAffected":137,"numAtRisk":554},{"groupId":"EG001","numEvents":179,"numAffected":122,"numAtRisk":559}]},{"term":"Injection-site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":563,"numAffected":304,"numAtRisk":554},{"groupId":"EG001","numEvents":480,"numAffected":271,"numAtRisk":559}]},{"term":"Injection-site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA version 20.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":181,"numAffected":118,"numAtRisk":554},{"groupId":"EG001","numEvents":121,"numAffected":82,"numAtRisk":559}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2013-04-04","uploadDate":"2018-07-30T08:54","filename":"Prot_SAP_000.pdf","size":1937361}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09","removedCountries":["Japan"]},"interventionBrowseModule":{"meshes":[{"id":"D000068857","term":"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18"}],"ancestors":[{"id":"D017778","term":"Vaccines, Combined"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D053918","term":"Papillomavirus Vaccines"},{"id":"D014765","term":"Viral Vaccines"}]}},"hasResults":true}